Transplantation without growth factor: Engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL)

Bone Marrow Transplantation

Volumn 40, Issue 10, 2007, Pages 989-993

  Gertz, M A ^a   Lacy, M Q ^a   Dispenzieri, A ^a   Hayman, S R ^a   Kumar, S K ^a   Leung, N ^a   Gastineau, D A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUCONAZOLE; GROWTH FACTOR; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; AMYLOIDOSIS; APHERESIS; ARTICLE; BACTEREMIA; CELL KINETICS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; ENGRAFTMENT; FEASIBILITY STUDY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPHIL COUNT; PRIORITY JOURNAL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; TREATMENT OUTCOME;

AMYLOIDOSIS; BACTEREMIA; COHORT STUDIES; FEMALE; FILGRASTIM; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HOSPITALIZATION; HUMANS; MALE; MINNESOTA; STEM CELL TRANSPLANTATION;

EID: 35748975944     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705848     Document Type: Article

References (23)

1. Jansen J, Hanks S, Thompson JM, Dugan MJ, Akard LP. Transplantation of hematopoietic stem cells from the peripheral blood. J Cell Mol Med 2005; 9: 37-50.
2. Gabrilove JL. An analysis of current neutropenia therapies, including pegfilgrastim. Clin Cornerstone 2006; 8 (Suppl 5): S19-S28.
3. Akard LP, Thompson JM, Dugan MJ, Wiemann M, Greenspan A, Hanks S et al. Matched-pair analysis of hematopoietic progenitor cell mobilization using G-CSF vs. cyclophosphamide, etoposide, and G-CSF: enhanced CD34 cell collections are not necessarily cost-effective. Biol Blood Marrow Transplant 1999; 5: 379-385.
4. Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P et al. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity. Wien Klin Wochenschr 2006; 118: 49-53.
5. Perotti C, Del Fante C, Viarengo G, Perlini S, Vezzoli M, Rodi G et al. Peripheral blood progenitor cell mobilization and collection in 42 patients with primary systemic amyloidosis. Transfusion 2005; 45: 1729-1734.
6. Leung N, Leung TR, Cha SS, Dispenzieri A, Lacy MQ, Gertz MA. Excessive fluid accumulation during stem cell mobilization: A novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood 2005; 106: 3353-3357; e-pub ahead of print 21 July 2005.
7. Dember LM, Sanchorawala V, Seldin DC, Wright DG, LaValley M, Berk JL et al. Effect of dose-intensive intravenous melphalan and autologous-blood stem-cell transplantation on AL amyloidosis-associated renal disease. Ann Intern Med 2001; 134: 746-753.
8. Oran B, Wright DG, Seldin DC, McAneny D, Skinner M, Sanchorawala V. Spontaneous rupture of the spleen in AL amyloidosis. Am J Hematol 2003; 74: 131-135.
9. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: Results of a prospective randomized trial. Bone Marrow Transplant 2004; 33 381-388.
10. Sanchorawala V, Wright DG, Seldin DG, Dember LM, Finn K, Falk RH et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637-642.
11. Burgstaler EA, Pineda AA, Winters JL. Hematopoietic progenitor cell large volume leukapheresis (LVL) on the Fenwal Amicus blood separator. J Clin Apher 2004; 19: 103-111.
12. Balducci L, Carreca I. The role of myelopoietic growth factors in managing cacer in the elderly. Drugs 2002; 62 (Suppl. 1): 47-63.
13. Crawford J. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy 2003; 23: 15S-19S.
14. Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT et al. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 2005; 35: 567-575 [Erratum in: Bone Marrow Transplant 2005; 35: 635].
15. Tarella C, Castellino C, Locatelli F, Caracciolo D, Corradini P, Falda M et al. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: Evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998; 21: 401-407.
16. Klaus J, Herrmann D, Breitkreutz I, Hegenbart U, Mazitschek U, Egerer G et al. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol 2007; 78: 21-28.
17. Ketterer N, Espinouse D, Chomarat M, Dumontet C, Moullet I, Rieux C et al. Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: Etiology and potential risk factors. Am J Med 1999; 106: 191-197.
18. Reich G, Mapara MY, Reichardt P, Dorken B, Maschmeyer G. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: Comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant 2001; 27: 525-529.
19. Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 143-147.
20. Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients. Br J Haematol 1998; 101: 766-769.
21. Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: A single centre prospective phase II study. Br J Haematol 2004; 127: 543-551.
22. Ojeda E, Garcia-Bustos J, Agaudo MJ, Quevedo E, Arrieta R, Jimenez V et al. Is filgrastim as useless after peripheral blood stem cell transplantation for adults as it could be for children? Blood 1999; 93: 3565-3566.
23. Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, et al British Society of Blood and Marrow Transplantation. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: A British Society of Blood and Marrow Transplantation study. Br J Haematol 2006; 134: 385-390; e-pub ahead of print 5 July 2006.